Research across Cardiomyopathy
Related studies from across the Cardiomyopathy family.
Aficamten improves echocardiographic measures of diastolic function in nonobstructive hypertrophic cardiomyopathy
Trial shows aficamten improves heart function in specific cardiomyopathy
This Phase 3 randomized controlled trial of 517 symptomatic patients with nonobstructive hypertrophic cardiomyopathy found that aficamten im…
A new trial shows that the drug aficamten improves heart muscle function and measurements in patients with a specific type of heart muscle d…
Acoramidis reduces risk of ACM and CVM regardless of baseline NT-proBNP and sTTR levels
New trial shows acoramidis works for heart muscle disease
This Phase 3 randomized controlled trial of 632 patients with transthyretin amyloid cardiomyopathy found that acoramidis reduced the risk of…
A new trial shows that the drug acoramidis helps patients with a specific heart condition regardless of their initial test results.
Heart Failure Evidence in Somalia Is Fragmented and Insufficient to Estimate National Burden
Review Identifies Common Causes of Heart Failure in Somalia
This scoping review synthesizes 12 studies on heart failure in Somalia, finding that evidence is geographically concentrated, methodological…
A review of 12 studies identifies key conditions like hypertension and heart disease that contribute to heart failure in the Somali region.
Black participation in hypertrophic cardiomyopathy trials is only 3.98% of the expected share
Black patients are underrepresented in heart muscle disease trials
This meta-analysis of 13 trials involving 1,780 participants identifies a significant disparity in Black representation within hypertrophic …
Black patients make up less than 4% of participants in heart muscle disease trials, despite much higher rates in the general population.
HDAC3 acts as a central epigenetic hub for Type 2 Diabetes and its complications
New research identifies a key protein linked to diabetes complications
This systematic review identifies HDAC3 as a critical regulator of immunometabolic homeostasis in Type 2 Diabetes. The review concludes that…
A specific protein called HDAC3 may play a central role in causing heart, kidney, and eye damage in people with Type 2 Diabetes.
Dystrophinopathy should be considered in adolescent males with nonischemic cardiomyopathy and heart failure
Heart failure treatment shows promise for a boy with muscular dystrophy
This case report describes a 17-year-old male with Duchenne muscular dystrophy and heart failure who showed LVEF improvement from 44% to 55%…
A 17-year-old boy with a rare muscle disease saw his heart function improve while receiving standard heart failure care.
Cardiac myosin inhibitors improve exercise capacity and health status in patients with hypertrophic cardiomyopathy
New heart medication shows promise for hypertrophic cardiomyopathy patients
This meta-analysis evaluated the impact of cardiac myosin inhibitors on adults with symptomatic non-obstructive hypertrophic cardiomyopathy.…
A new class of heart drugs may improve exercise capacity and quality of life for people with a specific heart muscle condition.
Conduction system pacing reduces heart failure hospitalization and cardiomyopathy risk compared to right ventricular pacing
Conduction system pacing may lower heart failure hospital risks
This meta-analysis of randomized controlled trials involving 1466 patients with preserved or mildly reduced LVEF found that conduction syste…
A new type of heart pacing could significantly lower the risk of heart muscle damage and hospital stays for patients with heart failure.
AI-empowered echocardiography shows promise for HCM diagnosis and risk prediction, but validation is lacking
AI Echocardiography Shows Promise for Heart Condition
This systematic review synthesizes AI-empowered echocardiography applications in hypertrophic cardiomyopathy, categorizing methods by comple…
AI-powered echocardiography may improve diagnosis and risk prediction for hypertrophic cardiomyopathy, but large-scale validation is still n…
Transthyretin stabilizers and RNA-silencing therapies attenuate cardiac remodeling in transthyretin amyloid cardiomyopathy
New Therapies May Slow Heart Damage in Amyloid Cardiomyopathy
This meta-analysis of 3646 adults with cardiac amyloidosis found that transthyretin stabilizers and RNA-silencing therapies are associated w…
Specific drug therapies may help stabilize heart structure and slow the progression of damage for adults with transthyretin amyloid cardiomy…
Gene, inflammation, and metabolic dysregulation drive pathophysiology in pediatric dilated cardiomyopathy
Gene, Inflammation, Metabolism Link in Child Heart Failure
This systematic review examines the role of the gene-inflammation-metabolism axis in pediatric dilated cardiomyopathy. The authors identify …
A new review links genes, inflammation, and metabolism in pediatric dilated cardiomyopathy, offering a roadmap for targeted treatments.
Exercise improves cardiorespiratory fitness and quality of life in patients with hypertrophic cardiomyopathy
Exercise improves heart health and fitness for HCM patients
This meta-analysis of 9,702 patients with hypertrophic cardiomyopathy (HCM) found that exercise is associated with increased peak oxygen con…
New research shows that structured exercise can improve heart fitness, body weight, and quality of life for people with hypertrophic cardiom…